4 / 28
Page 26
Notes:
conferenceseries
.com
Volume 9, Issue 9 (Suppl)
J Cancer Sci Ther, an open access journal
ISSN: 1948-5956
World Cancer 2017
October 19-21, 2017
25
th
WORLD CANCER CONFERENCE
October 19-21, 2017 | Rome, Italy
Re-irradiation in cancer - Can amifostine help us?
Oliver Micke
1
, Jens Büntzel
2
and
Henno Welgemood
3
1
Franziskus Hospital Bielefeld, Germany
2
Südharz Klinikum Nordhausen, Germany
3
Clinigen Group plc, UK
A
second irradiation course has been established for the treatment of recurrent head and neck cancer since more than
5 decades. 24-month survival rates are limited to 30-40%. Severe acute and late toxicities are observed in up to 50%
of all treated patients. Does selective cytoprotection with amifostine offer a way to reduce the high toxicity profile? We re-
analyzed the data of three earlier published mono-centric studies which had combined re-irradiation of a solid tumor with the
application of 500 mg amifostine IV before daily radiotherapy. 42/53 patients received re-irradiation because of head and neck
cancer disease. 11 have had other solid tumors (rectal cancer 5, cervical cancer 2, endometrial cancer 2, uterus sarcoma 1, and
prostate cancer 1). All head and neck cancer patients received additional chemotherapy for radio-sensitizing. The therapy was
possible in all patients without serious adverse events due to amifostine. The combination of chemo- and radiotherapy was
possible in all treated patients. The total irradiation doses were >110 Gy for both courses. Acute mucosal and skin toxicities
(mucositis, stomatitis, diarrhea, dermatitis, cystitits and proctitis) were reduced to grade 1 / 2 level in 49/53 patients. Grade 3
/4 toxicities were seen in only <10% (n=4). No objective data were available for late toxicities and survival. In conclusion, we
suggest initiating new research on the combination of amifostine and re-irradiation of solid tumors. We await the reduction of
acute toxicity and positive impact on late toxicity profile as well as effect of irradiation in this situation.
Biography
Oliver Micke has completed his PhD from Muenster University Hospital in 2006. He is Head of the Department for Radiotherapy and Radiation Oncology at
Franziskus Hospital Bielefeld since 2006. In addition, he is the Medical Director of Franziskus Hospital Bielefeld, a premier teaching hospital of the Medical
University of Hanover (MHH). He has published more than 200 papers in reputed national and international journals and has been serving as Reviewer as well as
an Editorial Board Member of repute.
strahlenklinik@web.deOliver Micke et al., J Cancer Sci Ther 2017, 9:9(Suppl)
DOI: 10.4172/1948-5956-C1-111